Efficacy and Safety of Murivenna Anal Infiltration Compared to Diltiazem Topical Application in Chronic Anal Fissure: Protocol for a Prospective, Randomized, Open-Label Clinical Trial.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES JMIR Research Protocols Pub Date : 2025-02-03 DOI:10.2196/63063
Pratap Shankar Km, Indu Puthan Purayil, Palengara Binitha, Amit Kumar Rai, Sophia Jameela, Azeem Ahmad, Chandra Sekhara Rao Bhogavalli, Narayanam Srikanth, Rabinarayan Acharya
{"title":"Efficacy and Safety of Murivenna Anal Infiltration Compared to Diltiazem Topical Application in Chronic Anal Fissure: Protocol for a Prospective, Randomized, Open-Label Clinical Trial.","authors":"Pratap Shankar Km, Indu Puthan Purayil, Palengara Binitha, Amit Kumar Rai, Sophia Jameela, Azeem Ahmad, Chandra Sekhara Rao Bhogavalli, Narayanam Srikanth, Rabinarayan Acharya","doi":"10.2196/63063","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anal fissure is a common proctologic condition that causes significant pain and anguish to patients, significantly impacting their quality of life and well-being. There are various treatment options for anal fissure, ranging from pharmacological agents that reduce anal sphincter tone to surgical interventions for cases resistant to medical management. Ayurvedic treatments have shown potential for the therapeutic management of anal fissure.</p><p><strong>Objective: </strong>This clinical study aims to analyze the efficacy and safety of murivenna anal infiltration compared to diltiazem topical application in chronic anal fissure.</p><p><strong>Methods: </strong>This is an open-labeled, randomized, controlled parallel group clinical trial with a sample size of 66 participants to be randomized and allocated in a 1:1 ratio to 2 groups. The intervention group will be treated with murivenna anal infiltration, and the control group will be treated with topical application of diltiazem for a period of 4 weeks. The primary outcome will be the proportion of participants demonstrating complete healing after 4 weeks of treatment. The secondary outcomes will be the proportion of participants demonstrating complete healing after 7 days and 14 days of treatment, change in pain at or after defecation, cessation of bleeding, and any recurrence during the study period. Any adverse events will also be recorded during the trial period.</p><p><strong>Results: </strong>The project was funded in July 2023, and the study period is 24 months. Participant recruitment started in December 2023. As of August 2024, we have enrolled 50 participants. The data analysis will be complete by June 2025, and the results are expected to be published by August 2025.</p><p><strong>Conclusions: </strong>High recurrence rates, adverse effects, incomplete healing, and the negative impact on patients' daily activities and quality of life underscore the need for alternative therapeutic options. Ayurveda offers potential for more sustainable relief with fewer adverse effects. Murivenna oil is a time-tested medicated oil effectively used by Ayurvedic physicians for various ulcers of traumatic and pathological origin. This study will provide scientific evidence on the efficacy and safety of murivenna anal infiltration; further, it can be incorporated into the cost-effective management of chronic anal fissure.</p><p><strong>Trial registration: </strong>Clinical Trials Registry India CTRI/2023/09/057330; https://tinyurl.com/y4ut9e8p.</p><p><strong>International registered report identifier (irrid): </strong>DERR1-10.2196/63063.</p>","PeriodicalId":14755,"journal":{"name":"JMIR Research Protocols","volume":"14 ","pages":"e63063"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Research Protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/63063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Anal fissure is a common proctologic condition that causes significant pain and anguish to patients, significantly impacting their quality of life and well-being. There are various treatment options for anal fissure, ranging from pharmacological agents that reduce anal sphincter tone to surgical interventions for cases resistant to medical management. Ayurvedic treatments have shown potential for the therapeutic management of anal fissure.

Objective: This clinical study aims to analyze the efficacy and safety of murivenna anal infiltration compared to diltiazem topical application in chronic anal fissure.

Methods: This is an open-labeled, randomized, controlled parallel group clinical trial with a sample size of 66 participants to be randomized and allocated in a 1:1 ratio to 2 groups. The intervention group will be treated with murivenna anal infiltration, and the control group will be treated with topical application of diltiazem for a period of 4 weeks. The primary outcome will be the proportion of participants demonstrating complete healing after 4 weeks of treatment. The secondary outcomes will be the proportion of participants demonstrating complete healing after 7 days and 14 days of treatment, change in pain at or after defecation, cessation of bleeding, and any recurrence during the study period. Any adverse events will also be recorded during the trial period.

Results: The project was funded in July 2023, and the study period is 24 months. Participant recruitment started in December 2023. As of August 2024, we have enrolled 50 participants. The data analysis will be complete by June 2025, and the results are expected to be published by August 2025.

Conclusions: High recurrence rates, adverse effects, incomplete healing, and the negative impact on patients' daily activities and quality of life underscore the need for alternative therapeutic options. Ayurveda offers potential for more sustainable relief with fewer adverse effects. Murivenna oil is a time-tested medicated oil effectively used by Ayurvedic physicians for various ulcers of traumatic and pathological origin. This study will provide scientific evidence on the efficacy and safety of murivenna anal infiltration; further, it can be incorporated into the cost-effective management of chronic anal fissure.

Trial registration: Clinical Trials Registry India CTRI/2023/09/057330; https://tinyurl.com/y4ut9e8p.

International registered report identifier (irrid): DERR1-10.2196/63063.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与地尔硫卓局部应用相比,Murivenna肛门浸润治疗慢性肛裂的疗效和安全性:一项前瞻性、随机、开放标签的临床试验方案。
背景:肛裂是一种常见的直肠疾病,给患者带来巨大的疼痛和痛苦,严重影响他们的生活质量和健康。肛裂有多种治疗选择,从减少肛门括约肌张力的药物到对药物治疗无效的手术干预。阿育吠陀疗法已经显示出治疗肛裂的潜力。目的:比较地尔硫卓外敷治疗慢性肛裂的疗效和安全性。方法:这是一项开放标记、随机对照、平行组临床试验,样本量为66名参与者,按1:1的比例随机分配到2组。干预组采用静脉肛门浸润治疗,对照组局部应用地尔硫卓治疗,疗程4周。主要结果将是4周治疗后显示完全愈合的参与者比例。次要结果将是在治疗7天和14天后显示完全愈合的参与者比例,排便时或排便后疼痛的变化,出血的停止以及研究期间的任何复发。任何不良事件也将记录在试验期间。结果:项目于2023年7月立项,研究时间为24个月。参与者招募于2023年12月开始。截至2024年8月,我们已经招募了50名参与者。数据分析将于2025年6月完成,结果预计将于2025年8月公布。结论:高复发率、不良反应、不完全愈合以及对患者日常活动和生活质量的负面影响强调了替代治疗方案的必要性。阿育吠陀提供了更可持续的缓解和更少的副作用的潜力。Murivenna油是一种经过时间考验的药物油,有效地用于阿育吠陀医生治疗各种创伤性和病理性溃疡。本研究将为肛内浸润术的有效性和安全性提供科学依据;此外,它可以纳入成本效益的管理慢性肛裂。试验注册:印度临床试验注册中心CTRI/2023/09/057330;https://tinyurl.com/y4ut9e8p.International注册报告标识符(irrid): DERR1-10.2196/63063。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.40
自引率
5.90%
发文量
414
审稿时长
12 weeks
期刊最新文献
Overcoming the HIV Pre-Exposure Prophylaxis Uptake Barrier With A Health Action Process Approach and Conditional Economic Incentives Among Men Who Have Sex With Men in 3 Chinese Cities: Protocol for a Randomized Controlled Trial. WhatsApp-Led mHealth Intervention for Hypertension Management Among Adults Aged 40 to 59 Years in Kerala, India: Protocol for a Mixed Methods Study. Objective Assessment of Financial Decision-Making With a Simulated Online Money Management Task in Older Adults: Protocol for a Prospective Observational Study. Children's Attitudes Toward Dementia: Protocol for a Cross-Sectional Study. Locus-Coeruleus Norepinephrine Functioning as a Predictor of Childhood Mental Health (LOCUS-MENTAL): Protocol for a Longitudinal Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1